WO2013012180A2 - 진세노사이드 Ｒｇ3 및 Ｒｈ2가 강화된 홍삼농축액 제조방법 - Google Patents
진세노사이드 Ｒｇ3 및 Ｒｈ2가 강화된 홍삼농축액 제조방법 Download PDFInfo
- Publication number
- WO2013012180A2 WO2013012180A2 PCT/KR2012/005032 KR2012005032W WO2013012180A2 WO 2013012180 A2 WO2013012180 A2 WO 2013012180A2 KR 2012005032 W KR2012005032 W KR 2012005032W WO 2013012180 A2 WO2013012180 A2 WO 2013012180A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- red ginseng
- ginsenoside
- ginseng liquid
- liquid concentrate
- acid
- Prior art date
Links
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 78
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 title claims abstract description 54
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 20
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 title claims abstract description 19
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 title claims abstract description 16
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 title claims abstract description 16
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 title claims abstract description 16
- 235000014666 liquid concentrate Nutrition 0.000 title abstract 10
- 238000000034 method Methods 0.000 claims abstract description 43
- 150000007524 organic acids Chemical class 0.000 claims abstract description 18
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 12
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 9
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 8
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000001630 malic acid Substances 0.000 claims abstract description 8
- 235000011090 malic acid Nutrition 0.000 claims abstract description 8
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000007062 hydrolysis Effects 0.000 claims abstract description 7
- 239000011975 tartaric acid Substances 0.000 claims abstract description 6
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 6
- 239000001384 succinic acid Substances 0.000 claims abstract description 3
- 239000012141 concentrate Substances 0.000 claims description 34
- 238000006243 chemical reaction Methods 0.000 claims description 14
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 235000011044 succinic acid Nutrition 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 abstract description 31
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 30
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 30
- 235000008434 ginseng Nutrition 0.000 abstract description 30
- 230000008569 process Effects 0.000 abstract description 19
- 206010028980 Neoplasm Diseases 0.000 abstract description 12
- 201000011510 cancer Diseases 0.000 abstract description 12
- 230000000144 pharmacologic effect Effects 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 4
- 239000008213 purified water Substances 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 238000007395 thrombosis prophylaxis Methods 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000010808 liquid waste Substances 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 description 18
- 235000017709 saponins Nutrition 0.000 description 18
- 150000007949 saponins Chemical class 0.000 description 18
- 229930182494 ginsenoside Natural products 0.000 description 14
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 239000002994 raw material Substances 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000020710 ginseng extract Nutrition 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- PVLHOJXLNBFHDX-XHJPDDKBSA-N Panaxadiol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(CC[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 PVLHOJXLNBFHDX-XHJPDDKBSA-N 0.000 description 7
- SYFJYASKXNAXKC-UHFFFAOYSA-N Panaxadiol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CCC34C SYFJYASKXNAXKC-UHFFFAOYSA-N 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 238000005903 acid hydrolysis reaction Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 5
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 description 4
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010025 steaming Methods 0.000 description 3
- 229960001367 tartaric acid Drugs 0.000 description 3
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical compound OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 description 1
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- -1 nitrogen-containing compound Chemical class 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Definitions
- the present invention relates to a method for preparing a red ginseng concentrate enriched with ginseng saponin components, and more particularly, to a method for preparing a red ginseng concentrate containing high concentrations of ginsenosides Rg3 and Rh2 as red ginseng liquid.
- Ginseng is botanically belonging to the genus Panax of the Araliaceae, a herb that has long been known for its efficacy and effectiveness in the Orient.
- a method of producing black ginseng by vesicles is known as a classical method in relation to the technology of strengthening saponin of a specific ingredient contained in ginseng, and there is a method by heat treatment of red ginseng concentrate and extract at high temperature and high pressure.
- the method has a disadvantage that the time according to the manufacturing process is too long, and the high temperature and high pressure treatment method can shorten the time according to the manufacturing process, but the cost of energy consumption increases due to the high temperature and high pressure, and the process stability is low. .
- the microorganism (lactic acid bacteria) method has the advantage that can selectively strengthen the specific saponin, but the selection and culture technology of lactic acid bacteria It is difficult, the process is complicated and difficult to manage, the hydrolysis method is different in the selectivity or conversion efficiency of a particular saponin according to the type of acid or enzyme, generally selectivity or conversion than the method by the microorganism Although the disadvantage is that the efficiency is rather low, the process is simple and the production cost can be significantly reduced. In particular, if the selection of an acid or enzyme suitable for a specific saponin conversion and the development of the optimum conditions of the process are the most competitive Technology.
- the process of steaming black ginseng with increased contents of Rg3 and Rh2 is carried out by carrying out the steaming process of the first and sixth times in the process of repeating the process under normal pressure and the pressure of 5 to 15 atmospheres.
- heat treatment under high pressure by using a method for producing black ginseng, which is uneconomical because it requires a long process time of 30 days or more under high temperature and high pressure conditions, and the Republic of Korea Patent Publication No.
- 10-2011 -0052940 describes a method for preparing a ginseng extract fraction enhanced with ginsenoside Rg3 by reacting ginsenoside Rb1-containing alcohol extract of ginseng with a mixture of water and acetic acid and then purifying it. This is because the amount of acetic acid used in the reaction is about 25% of the volume of the reaction solution, which may not only reduce product quality but also enhance only ginsenoside Rg3. The process is complicated because it uses a purification method such as 20 columns.
- Korean Patent Laid-Open Publication No. 10-2010-0111457 discloses an acidic singer containing ginsenoside Rg3 by preparing white ginseng extract from white ginseng and inducing conversion of Rg3 from white ginseng extract by acid hydrolysis and heat treatment of the white ginseng extract.
- a method for preparing a decomposed white ginseng extract is disclosed, which is an acid hydrolyzed white ginseng extract with an increased content of ginsenoside Rg3, but the acid hydrolysis of PD (panaxadiol) -based saponins using citric acid results in Rg3.
- ginseng generally contains about 33 kinds of saponins, and contains 4% to 6% by content, and can be efficiently manufactured in a simpler process in order to produce a product enhanced with a specific saponin. Developing such technology would be desirable for future technological progress.
- the present invention improves the drawbacks of the above-described prior art and prior art processes that are cumbersome and costly, and not only increases the specific saponin conversion rate but also enhances ginsenosides Rg3 and Rh2 simultaneously by a simpler method. It is an object of the present invention to provide a method for producing red ginseng concentrate, and more specifically, ginsenoside having excellent cancer prevention and anticancer activity among ginsenoside components present in red ginseng extract by a method of acid hydrolysis of red ginseng extract. It is an object of the present invention to provide a method for producing red ginseng concentrates with the Rg3 and Rh2 components at the same time.
- the method for producing the red ginseng concentrate according to the present invention consists of preparing a red ginseng concentrate at the same time strengthening the ginsenoside Rg3 and Rh2 components by mixing the organic acid with the red ginseng extract and hydrolysis reaction, more in detail
- the red ginseng concentrate which is enriched with ginsenosides Rg3 and Rh2 by simultaneously hydrolyzing the organic acid selected from malic acid, tartaric acid and succinic acid, with red ginseng extract. It consists of manufacturing.
- the red ginseng extract selected as a raw material for the preparation of the red ginseng concentrate according to the present invention uses a red ginseng extract prepared according to well-known extraction methods in the technical field to which the present invention belongs, and is not particularly limited, specifically, dried red ginseng
- the extract was prepared by extracting and concentrating the fourth solvent at 70 ° C. to 90 ° C. with an alcohol having a purity of 30% to 70%.
- the content of ginsenoside Rb1 is 24 mg / g and the solid content is 70% by weight.
- ginseng is composed of 3-6% saponin, 12-15% nitrogen-containing compound, 1-2% fat-soluble component, 50-60% carbohydrate-based, and other 4-6%.
- Specific components according to species are physiologically active substances, containing about 3-6% of ginsenoside, a kind of saponin, and ginsenosides based on molecular structure (Panaxadiol: PD), Panaxatriol (PT), Oleanan (Oleanane), and about 33 species have been reported [Latest Korea Ginseng, Korea Ginseng and Tobacco Research Institute, 1996]. Detailed components of ginseng related to the above are shown in [Table 1].
- ginsenoside Rg3 contains 0.003mg / g of white ginseng products and 0.2 mg / g of red ginseng products.
- the content of Rg3 is more than 70 times higher, and the content of ginsenoside Rh2 is 0mg / g of white ginseng products and 0.01 mg / g of red ginseng products, so the content of ginsenoside Rh2 of red ginseng products is higher than that of white ginseng products.
- This content is about 100 times higher ⁇ 4 Chem. Pharm. Bull. 45, 1039-1045 (1997), Chem. Pharm. Bull. 46, 647-654 (1998), Chem. Pharm. Bull. 49, 1452-1456 (2001).
- ginseng include central nervous system disease, anti-anxiety, nervous system, drug addiction, vascular effect, alcohol detoxification, lipid metabolism and fatigue, antidiabetic, hyperlipidemia, antiviral, immune enhancement, sexual function improvement, anticancer and cancer prevention
- panaxadiol (PD) -based saponins represented by ginsenoside Rb1
- PD panaxadiol
- Panaxatriol (PT) -based saponins represented by cenoside Rg1
- PT pharmacological effects of each saponin are reported to be different and show new efficacy.
- Pharmacological effects of the main saponin components are shown in Table 2 below.
- Another feature of the present invention is that by hydrolyzing with organic acids beneficial to the human body, there is no need for additional use and removal of purified water for purification, and no waste solution is generated, resulting in an efficient and simplified process. It is characterized in that to produce a red ginseng concentrate which is enhanced at a high concentration at the same time Rg3 and Rh2 components.
- the reaction is carried out at a temperature of 90 ° C. to 95 ° C. for 3 hours to 48 hours at atmospheric pressure, and more preferably 24 to 48 hours.
- the amount of the organic acid used in the reaction is preferably added in a ratio of 1% by weight to 5% by weight based on the raw red ginseng extract.
- the red ginseng concentrate production method is to provide a red ginseng concentrate at the same time strengthening the Rg3 and Rh2 component, which is particularly effective in anticancer, cancer treatment, anticancer toxicity reduction, cancer prevention, immune enhancement and thrombosis prevention.
- Red ginseng concentrate has the effect of showing better efficacy, such as cancer treatment, cancer prevention, immune enhancement, and also, by using a red ginseng extract that is more pharmacologically effective than white ginseng by hydrolyzing with organic acids beneficial to the human body, Since there is no need for additional use and removal of purified water, and no waste solution is generated, red ginseng concentrate is prepared by strengthening the Rg3 and Rh2 components at a high concentration simultaneously by an efficient and simplified process.
- red ginseng extract which is a raw material used in the present invention
- red ginseng concentrate prepared according to the present invention.
- A is HPLC data for standards of ginsenosides Rg3 and Rh2
- B is HPLC data for Rg3 and Rh2 of the raw red ginseng extract used in the present invention.
- C is HPLC data for red ginseng concentrate enriched in Rg3 and Rh2 by malic acid in the present invention.
- D is HPLC data for red ginseng concentrate enriched in Rg3 and Rh2 by vitric acid in the present invention.
- E is HPLC data for Rg3 and Rh2 enhanced red ginseng concentrate by succinic acid in the present invention
- the embodiment of the present invention used a raw red ginseng extract prepared by Daedong Goryeo Co., Ltd. (applicant of the present invention) in Geumsan-gun, Chungnam, in particular, the red ginseng extract used in the embodiment of the present invention is 4 in the Daedong Goryeo Co., Ltd. Since it is mass producing ⁇ 10 tons / month, no additional process for raw material supply is required, which can significantly lower production costs.
- the extract obtained in each extraction step is extracted as a extract concentrated in the range of 60 ⁇ 70% by weight, less than 2% by weight, ginsenoside Rg1 + Rb1 content 4mg / g ⁇ 50mg / g solid content using a vacuum condenser
- the content of ginsenosides Rg3 and Rh2 in the extract obtained in each step extraction process was analyzed by HPLC (High Performance Liquid Chromatography) equipped with UVD (Ultra Visible Detector) in [Table 3] and [Table 4] below. Analysis was carried out by the analysis conditions and the content calculation formula as shown.
- red ginseng concentrate was prepared in the same manner as in ⁇ Example 1>, and the changes of Rg3 and Rh2 according to the amount of added organic acid and reaction time were investigated. Table 6].
- red ginseng concentrate was prepared in the same manner as in ⁇ Example 1>, and the changes of Rg3 and Rh2 according to the amount of added organic acid and reaction time were investigated. 7].
- Rg3 is in the range of 17.1 mg / g to 21.4 mg / g and Rh2.
- Rg3 and Rh2 components were simultaneously enhanced from 21.4 mg / g to 25.7 mg / g, while citric acid and threonine (hydrochloric acid) were hydrolyzed under the same reaction conditions (reaction temperature, reaction time and amount of organic acid added).
- threonine and alanine are enhanced in Rg3 from 8.5 mg / g to 17.1 mg / g, but Rh2 is absent, so citric acid, threonine and alanine simultaneously enhance Rg3 and Rh2 components. It was evaluated that it is not applicable to the method of the present invention.
- red ginseng extract is very useful as a raw material for the organic acid hydrolysis reaction according to the present invention. It was evaluated as advantageous.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Animal Behavior & Ethology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2011-0072609 | 2011-07-21 | ||
| KR1020110072609A KR101106487B1 (ko) | 2011-07-21 | 2011-07-21 | 진세노사이드 Ｒｇ3 및 Ｒｈ2가 강화된 홍삼농축액 제조방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2013012180A2 true WO2013012180A2 (ko) | 2013-01-24 |
| WO2013012180A3 WO2013012180A3 (ko) | 2013-03-14 |
Family
ID=45614379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2012/005032 WO2013012180A2 (ko) | 2011-07-21 | 2012-06-26 | 진세노사이드 Ｒｇ3 및 Ｒｈ2가 강화된 홍삼농축액 제조방법 |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101106487B1 (de) |
| WO (1) | WO2013012180A2 (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106924276A (zh) * | 2017-05-09 | 2017-07-07 | 西北大学 | 一种人参皂苷组合物及其在治疗白癜风中的应用 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101508271B1 (ko) * | 2013-05-22 | 2015-04-06 | 성신비에스티(주) | 홍삼 추출물을 함유하는 떡 및 뻥튀기 과자의 제조방법 |
| KR101577111B1 (ko) * | 2013-08-13 | 2015-12-11 | 주식회사 한국인삼공사 | 진세노사이드 Rh4 강화 분획물을 유효성분으로 함유하는 항염 또는 항산화용 약학적 조성물 |
| KR101617432B1 (ko) | 2013-11-26 | 2016-05-02 | 주식회사 티이바이오스 | 진세노사이드 Rg3를 다량 함유하는 홍삼 농축액의 제조 방법 |
| KR102597682B1 (ko) * | 2020-12-29 | 2023-11-02 | 재단법인 금산인삼약초산업진흥원 | 진세노사이드 함량이 증진된 홍삼농축물 및 이의 제조방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040034350A (ko) * | 2003-05-23 | 2004-04-28 | (주)바이오피아 | 면역 및 항암증진에 효과가 있는 바이탈지의 제조방법 |
| KR100789678B1 (ko) * | 2005-10-07 | 2008-01-02 | (주)예당바이오 | 김치 유산균을 이용한 발효인삼 또는 발효홍삼의 제조방법 |
| KR20060060643A (ko) * | 2006-05-04 | 2006-06-05 | (주)바이오피아 | 홍삼엑스의 산처리 및 온도처리에 의한 기능성사포닌 함량증대 |
| KR101052574B1 (ko) * | 2008-11-04 | 2011-07-29 | 씨제이제일제당 (주) | 인삼으로부터 진세노사이드 Ｒｇ1 또는 Ｒｂ1이 강화된 추출물 분획을 제조하는 방법 |
| KR100992800B1 (ko) * | 2010-05-14 | 2010-11-08 | 주식회사 지씨에이치앤피 | 미량의 진세노사이드 성분이 증가된 신규한 가공인삼 또는 가공인삼추출물의 제조방법 |
-
2011
- 2011-07-21 KR KR1020110072609A patent/KR101106487B1/ko active Active
-
2012
- 2012-06-26 WO PCT/KR2012/005032 patent/WO2013012180A2/ko active Application Filing
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106924276A (zh) * | 2017-05-09 | 2017-07-07 | 西北大学 | 一种人参皂苷组合物及其在治疗白癜风中的应用 |
| CN106924276B (zh) * | 2017-05-09 | 2021-03-19 | 西北大学 | 一种人参皂苷组合物及其在治疗白癜风中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101106487B1 (ko) | 2012-01-20 |
| WO2013012180A3 (ko) | 2013-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3111470B2 (ja) | 新規ポリペプチド化合物およびその製造法 | |
| WO2013012180A2 (ko) | 진세노사이드 Ｒｇ3 및 Ｒｈ2가 강화된 홍삼농축액 제조방법 | |
| CN102443027B (zh) | 果糖基化葛根素及其制备方法与用途 | |
| CN100396783C (zh) | 络石藤的木脂素苷元总提取物的提取工艺方法及其产品 | |
| CN113004297B (zh) | 二萜生物碱类化合物及其提取方法和应用 | |
| WO2012061984A1 (zh) | 制备芍药内酯苷和芍药苷的方法 | |
| CN1384088A (zh) | 一种从虎杖植物中提取白藜芦醇的制备方法 | |
| CN103833714B (zh) | 木犀草素、木犀草苷、木犀草素芸香糖苷半合成的方法 | |
| CN1053609A (zh) | 灯盏花素片剂原料药的提取工艺 | |
| CN100457770C (zh) | 二丁酰环磷腺苷钙的精制方法 | |
| JP2008212137A (ja) | 生物転換法を利用したペリヌスリンテウス菌糸体の液体培養による人参からの新規のジンセノサイド製造方法 | |
| CN113897406A (zh) | 一种从红景天粉末中提取并纯化红景天苷的方法 | |
| US20200317822A1 (en) | Method for Preparing Arabinogalacturonan from Tangerine Peel | |
| CN110642863B (zh) | 5,5,6型ptm类化合物及其制备方法和用途 | |
| WO2011059212A2 (en) | Preparation method of ginseng and red ginseng concentrates containing the increased amount of compound k by using pectinex | |
| KR101158846B1 (ko) | 진세노사이드 컴파운드 케이의 제조방법 | |
| CN100999754A (zh) | 一种植物雌激素－肠二醇的制备方法 | |
| CN107226870A (zh) | 牛膝糖聚合物及其制备方法和应用 | |
| CN104592185A (zh) | 荸荠皮提取槲皮素的方法 | |
| CN104327034B (zh) | 5位和7位酯基儿茶素分子选择性制备方法 | |
| CN110882246B (zh) | 不同生物活性的黄连生物碱的提取方法及应用 | |
| CN102295677A (zh) | 北美盐角草中一种新的降三萜皂苷及其制备方法和用途 | |
| CN104059950B (zh) | 一种化合物的制备方法 | |
| CN106588944B (zh) | 一种藏药内生真菌来源的化合物及其制备方法和应用 | |
| CN1149587A (zh) | 人参寡糖素、人参单体寡糖及其制备工艺和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12815518 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12815518 Country of ref document: EP Kind code of ref document: A2 |